These trials led to the current international recommendation that patients with T2DM and cardiovascular disease should receive a SGLT2 inhibitor along with metformin regardless of baseline or personalized glycosylated hemoglobin (HbA1C) levels. The gene discussed is SLC5A2; the disease is cardiovascular disorder.